The real clinical problem Veru is betting on is not whether semaglutide works, but what it leaves behind. GLP-1 receptor agonists reliably strip away fat, but in older patients with already-limited muscle reserves, they also erode lean mass and physical function, creating a paradox where successful weight loss accelerates the very frailty that most threatens long-term health in that population. Veru has now fully enrolled more than 200 patients aged 65 and older with BMI at or above 35 into its Phase 2b PLATEAU trial, testing whether oral enobosarm 3 mg added to initiating semaglutide treatment can shift that equation.
The design is tighter than the earlier QUALITY study, which enrolled patients already on semaglutide. PLATEAU captures subjects at treatment initiation, running 68 weeks to a primary endpoint of percent change in total body weight, with DXA-measured fat mass, lean mass, stair-climb performance, mobility, bone mineral density, and HbA1c as key secondaries. That endpoint structure reflects the “tissue selective” hypothesis directly: the trial needs to show not just that the combination preserves muscle, but that muscle preservation translates into actual incremental weight reduction beyond what Wegovy alone produces. An interim analysis at 32 weeks, expected in Q1 2027, will assess the lean and fat mass trajectory before the final topline readout in Q4 2027.
The predecessor QUALITY study did provide meaningful signal. In 168 patients aged 60 and older, enobosarm plus semaglutide met its primary endpoint with a statistically significant reduction in lean mass loss versus semaglutide alone (p=0.002), while also producing greater fat loss during the 16-week active period. The maintenance extension further showed that enobosarm monotherapy slowed weight regain after GLP-1 discontinuation. PLATEAU has to replicate those lean-mass findings in a larger cohort and over a longer window, against a more demanding combined weight endpoint, with patients who specifically have the severe obesity and advanced age that made QUALITY’s results clinically interesting in the first place.
The competitive pressure here is structural. Both semaglutide and tirzepatide are entrenched in the obesity market, and no SARM combination strategy has yet earned regulatory approval alongside them. Veru’s leverage depends entirely on the Q1 2027 interim lean-mass data. If the DXA readout reproduces QUALITY’s separation between arms, it validates the physiological thesis and provides the dose-response clarity needed to plan a Phase 3. If that separation narrows at 32 weeks, the longer 68-week endpoint becomes a much harder argument. The interim is the number that matters.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
